Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-046749
Filing Date
2025-03-28
Accepted
2025-03-28 16:01:20
Documents
78
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K fbrx-20241231.htm   iXBRL 10-K 2462976
2 EX-10.16 fbrx-ex10_16.htm EX-10.16 472730
3 EX-10.17 fbrx-ex10_17.htm EX-10.17 21677
4 EX-19.1 fbrx-ex19_1.htm EX-19.1 175563
5 EX-21.1 fbrx-ex21_1.htm EX-21.1 7853
6 EX-23.1 fbrx-ex23_1.htm EX-23.1 5196
7 EX-31.1 fbrx-ex31_1.htm EX-31.1 16769
8 EX-31.2 fbrx-ex31_2.htm EX-31.2 16889
9 EX-32.1 fbrx-ex32_1.htm EX-32.1 9681
10 EX-32.2 fbrx-ex32_2.htm EX-32.2 9560
11 EX-97.1 fbrx-ex97_1.htm EX-97.1 54619
  Complete submission text file 0000950170-25-046749.txt   10175658

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fbrx-20241231.xsd EX-101.SCH 1186149
81 EXTRACTED XBRL INSTANCE DOCUMENT fbrx-20241231_htm.xml XML 1595757
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38052 | Film No.: 25785736
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)